A zinc Schiff base complex inhibits cancer progression both in vivo and in vitro by inducing apoptosis.

A zinc Schiff base complex inhibits cancer progression both in vivo and in vitro by inducing apoptosis.

Environ Toxicol Pharmacol. 2017 Nov 06;56:383-392

Authors: Banerjee A, Banerjee K, Sinha A, Das S, Majumder S, Majumdar S, Choudhuri SK

Abstract
Cancer chemotherapy suffers from selectivity and undesired toxicity of the drugs. Since zinc is a biocompatible tracer element and cysteine derivatives are used in cancer chemoprevention, we intend to develop a complex of zinc and cysteine-derivatives as potent, non-toxic anticancer agents. Herein, we synthesized and characterized cysteine based ligand, 2-[(2-Hydroxy-3-methoxy-benzylidene)-amino]-3-mercapto-propionic acid and its Zn-complex, which are found to be non-toxic towards normal human PBMC. Data also revealed that only Zn-complex exhibited remarkable apoptosis in drug-sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 cancer cells as assessed by MTT, Cell cycle and AnnexinV binding assay. Moreover, Zn-complex altered ROS and GSH level of the respective cell lines. Finally, treatment of Zn-complex in Swiss albino mice did not show any systemic toxicity in preliminary trials in normal mice and remarkably increased the life-span of EAC bearing mice. In conclusion, the synthesized Zn-complex may be developed for efficacious, multidrug resistance reversal, non-toxic chemotherapeutic agents in future.

PMID: 29145169 [PubMed - as supplied by publisher]

http://ift.tt/2zenA6I